LGR5:癌症转移和化疗耐药性的新兴治疗标
Wanqi Wang1, Noor A Lokman1, Simon C Barry1,2
1Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, 5005, Australia.
Cancer metastasis reviews
|January 17, 2025
概括
富含白的G重复蛋白结合受体5 (LGR5) 是癌症干细胞标记物,对瘤进展和药物耐药性至关重要. 准LGR5对癌症治疗有希望,尽管它的效果复杂且取决于环境.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症干细胞研究研究
背景情况:
- 癌症干细胞 (CSCs) 驱动瘤的进展和治疗耐药性.
- 富含白的G重复蛋白结合受体5 (LGR5) 是各种癌症中验证的CSC标志物.
- 尤其是通过WNT/β-catenin通路传递的LGR5信号,会影响癌症的发展.
研究的目的:
- 审查LGR5在癌症中的表达和功能.
- 阐明由LGR5.5调节的分子机制.
- 探索LGR5在化疗耐药性和潜在治疗策略中的作用.
主要方法:
- 对不同类型癌症LGR5表达和功能研究的文献综述.
- 通过LGR5.5调节的分子通路的分析.
- 检查LGR5与治疗结果的关联.
主要成果:
- 在许多癌症中,LGR5促进癌细胞迁移,入侵,转移和血管生成.
- LGR5与化疗耐药性有关.
- 存在上下文依赖的角色,LGR5有时会激活瘤抑制途径或LGR5阴性细胞促进进展.
结论:
- 准LGR5是一个有希望的抗癌治疗策略.
- LGR5的功能影响是复杂的,因癌症类型,瘤微环境和分子相互作用而有所不同.
- 需要进一步的研究,以充分理解和利用LGR5信号来有效治疗癌症.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


